BioSpace News Archive

Nunzi Pharmaceutical Corporation (OTC:NUNZ) entered into a License Agreement with Michael Mitsunaga as stated in the 8K filing of 08/05/2021.

ASLAN Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced financial results for the second quarter ended June 30, 2021, and provided an update on recent corporate activities.

AlloVir, a late clinical-stage cell therapy company, reported financial results for the second quarter ended June 30, 2021.

Oncolytics Biotech® Inc. announced its financial results and development highlights for the quarter ended June 30, 2021.

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced that it will release second quarter 2021 financial results Friday, Aug. 13, 2021.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.

EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III, Inc., a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, announced that they have entered into a definitive business combination agreement.

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, reported financial results for the second quarter ended June 30, 2021.

Orthofix Medical Inc. reported its financial results for the quarter ended June 30, 2021.

NeoGenomics, Inc., a leading provider of cancer-focused genetics testing services, announced its second-quarter results for the period ended June 30, 2021.